These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24843561)

  • 1. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.
    Bando Y; Kanehara H; Aoki K; Hisada A; Toya D; Tanaka N
    J Diabetes Investig; 2012 Mar; 3(2):170-4. PubMed ID: 24843561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hyperglycemia may attenuate the serum-uric-acid-lowering effect of low-dose febuxostat in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Toyama H; Kanehara H; Hisada A; Okafuji K; Toya D; Tanaka N
    Diabetol Int; 2016 Sep; 7(3):308-313. PubMed ID: 30603278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
    Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.
    Iwasaki T; Kessoku T; Higurashi T; Taguri M; Yoneda M
    Diabetol Int; 2018 Jul; 9(3):189-195. PubMed ID: 30603366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks.
    Hamaguchi T; Koga M; Murai J; Saito H; Tamada D; Kurebayashi S; Katsuno T; Miyagawa J; Namba M
    J Diabetes Investig; 2012 Mar; 3(2):175-8. PubMed ID: 24843562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus.
    Kubota A; Matsuba I; Saito T; Nabe K; Seino Y
    J Diabetes Investig; 2011 Oct; 2(5):377-80. PubMed ID: 24843517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.
    Fujita N; Tsujii S; Kuwata H; Kurokawa R; Matsunaga S; Okamura S; Mashitani T; Furuya M; Kitatani M; Ishii H
    J Diabetes Investig; 2012 Mar; 3(2):164-9. PubMed ID: 24843560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.
    Kashiwagi A; Kadowaki T; Tajima N; Nonaka K; Taniguchi T; Nishii M; Ferreira JC; Amatruda JM
    J Diabetes Investig; 2011 Oct; 2(5):381-90. PubMed ID: 24843518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes.
    Tajiri Y; Kawano S; Hirao S; Oshige T; Iwata S; Ono Y; Inada C; Akashi T; Hayashi H; Sato Y; Tojikubo M; Yamada K
    Int Sch Res Notices; 2014; 2014():639489. PubMed ID: 27419209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.
    Ishikawa M; Takai M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2015 Aug; 7(8):607-12. PubMed ID: 26124906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
    Kanamori A; Matsuba I
    J Clin Med Res; 2013 Jun; 5(3):217-21. PubMed ID: 23671547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
    Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E
    J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 6-month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort study.
    Katsuyama H; Sako A; Adachi H; Hamasaki H; Yanai H
    J Clin Med Res; 2015 Jun; 7(6):479-84. PubMed ID: 25883713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes.
    Ohmura H; Mita T; Taneda Y; Sugawara M; Funayama H; Matsuoka J; Watada H; Daida H;
    J Clin Med Res; 2015 Apr; 7(4):211-9. PubMed ID: 25699116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin.
    Chung HS; Suh S; Kim MY; Kim SK; Kim HK; Lee JI; Hur KY; Kim JH; Min YK; Lee MS; Kim KW; Kim SW; Chung JH; Lee MK
    J Diabetes Investig; 2014 Feb; 5(1):51-9. PubMed ID: 24843737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Ther; 2015 Jun; 6(2):213-26. PubMed ID: 26014844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.